ArticleMolecular endocrinology (Baltimore, Md.)2012
Regulation of microRNA-375 by cAMP in pancreatic β-cells.
Article in Molecular endocrinology (Baltimore, Md.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 58 citations in OpenAlex.
- MicroRNAs in chronic pediatric diseases (Review).Experimental and therapeutic medicine · 2024Review
- Beta-cell death and dysfunction drives hyperglycaemia in organ donors.Diabetes, obesity & metabolism · 2023Article
- Article
- Liraglutide suppresses obesity and promotes browning of white fat via miR-27bThe Journal of international medical research · 2021Article
- miR-375 Promotes Pancreatic DifferentiationStem cells international · 2021Article
- Molecular Mechanisms of Nutrient-Mediated Regulation of MicroRNAs in Pancreatic β-cells.Frontiers in endocrinology · 2021Review
- Vildagliptin, a dipeptidyl peptidase-4 inhibitor, attenuated endothelial dysfunction through miRNAs in diabetic rats.Archives of medical science : AMS · 2021Article
- Multi-omics profiling reveals microRNA-mediated insulin signaling networks.BMC bioinformatics · 2020Article
- Type of training has a significant influence on the GH/IGF-1 axis but not on regulating miRNAs.Biology of sport · 2020Article
- Hotspots of Aberrant Enhancer Activity in Fibrolamellar Carcinoma Reveal Candidate Oncogenic Pathways and Therapeutic Vulnerabilities.Cell reports · 2020Article
- Beta cell secretion of miR-375 to HDL is inversely associated with insulin secretion.Scientific reports · 2019Article
- MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar Carcinoma.Cellular and molecular gastroenterology and hepatology · 2019Article
- Is miRNA-375 a promising biomarker for early detection and monitoring of patients with type 2 diabetes?Archives of medical sciences. Atherosclerotic diseases · 2018Article
- Glucagon Like Peptide 1 and MicroRNA in Metabolic Diseases: Focusing on GLP1 Action on miRNAs.Frontiers in endocrinology · 2018Review
- Micromanaging Glucose Tolerance and Diabetes.Advanced pharmaceutical bulletin · 2017Review
- MicroRNAs and metabolic disorders - where are we heading?Archives of medical science : AMS · 2017Article
- MicroRNAs in heart failure: Non-coding regulators of metabolic function.Biochimica et biophysica acta · 2016Review
- Activation of β-adrenergic receptors is required for elevated α1A-adrenoreceptors expression and signaling in mesenchymal stromal cells.Scientific reports · 2016Article
- Integrator of Stress Responses Calmodulin Binding Transcription Activator 1 (Camta1) Regulates miR-212/miR-132 Expression and Insulin Secretion.The Journal of biological chemistry · 2016Article
- Modulation of mesenchymal stem cells with miR-375 to improve their therapeutic outcome during scar formation.American journal of translational research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
MicroRNA-375 (miR-375) is necessary for proper formation of pancreatic islets in vertebrates and is necessary for the development of β-cells in mice, but regulation of miR-375 in these cells is poorly understood. Here, we show that miR-375 is transcriptionally repressed by the cAMP-protein kinase A (PKA) pathway and that this repression is mediated through a block in RNA polymerase II binding to the miR-375 promoter. cAMP analogs that are PKA selective repress miR-375, as do cAMP agonists and the glucagon-like peptide-1 receptor agonist, exendin-4. Repression of the miR-375 precursor occurs rapidly in rat insulinoma INS-1 832/13 cells, within 15 min after cAMP stimulation, although the mature microRNA declines more slowly due to the kinetics of RNA processing. Repression of miR-375 in isolated rat islets by exendin-4 also occurs slowly, after several hours of stimulation. Glucose is another reported antagonist of miR-375 expression, although we demonstrate here that glucose does not target the microRNA through the PKA pathway. As reported previously, miR-375 negatively regulates insulin secretion, and attenuation of miR-375 through the cAMP-PKA pathway may boost the insulin response in pancreatic β-cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.